Different Antiviral Potencies of BV‐araU and Related Nucleoside Analogues against Herpes Simplex Virus Type 1 in Human Cell Lines and Vero Cells

Machida, Haruhiko; Nishitani, Makiko; Suzutani, Tatsuo; Hayashi, Kozaburo

doi:10.1111/j.1348-0421.1991.tb01618.x

Cited by 15 publications

(7 citation statements)

References 13 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar observations were made in assay systems using cancer cell lines (11,17,18). Since malignant tumor cells grow rapidly and have large nucleoside pools compared with diploid cells, nucleoside analogues show lower activities in cancer cells than in normal cells.…”

Section: Discussionsupporting

confidence: 77%

Evaluation of Antiherpetic Compounds Using a Gastric Cancer Cell Line: Pronounced Activity of BVDU against Herpes Simplex Virus Replication

Kodama

Igarashi

Mori

et al. 1996

Microbiology and Immunology

View full text Add to dashboard Cite

We developed a rapid and simple method for the screening of antiviral agents against herpes simplex virus (HSV) in a model of gastrointestinal herpetic infection in vitro. This method was based on inhibition of HSV-induced cytopathogenicity in gastric adenocarcinoma MKN-28 cells, as monitored by an MTT colorimetric assay. From the various compounds that were evaluated for their activity against HSV-1 and HSV-2, brivudine (BVDU) emerged as the most effective. When the 50% effective concentration (EC50)

show abstract

Section: Discussionsupporting

confidence: 77%

Evaluation of Antiherpetic Compounds Using a Gastric Cancer Cell Line: Pronounced Activity of BVDU against Herpes Simplex Virus Replication

Kodama

Igarashi

Mori

et al. 1996

Microbiology and Immunology

View full text Add to dashboard Cite

show abstract

“…Though BV-araU is a dThd analog, VZV plaque was almost completely suppressed by about'3 ,uM BV-araU even in the presence 100 ,uM dThd. This contrasted with the finding on anti-HSV-l activity of BV-araU, which was nullified with 100 ,uM dThd (11).…”

contrasting

confidence: 54%

“…Anti-VZV potency of BV-araU was determined as described previously (9,10 (11,20). dThd reduced the anti-VZV potency of BV-araU at higher concentrations but not lower (Table 2).…”

mentioning

confidence: 99%

In vitro drug combination of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil with anti-human immunodeficiency virus or anticancer nucleosides

Machida

Ashida

Ikeda

et al. 1992

Antimicrob Agents Chemother

View full text Add to dashboard Cite

l-,-D-Arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and E-5-(2-bromovinyl)uracil, a metabolite of BV-araU, did not affect either the anti-human immunodeficiency virus activity or the cytotoxicity of azidothymidine in MT-4 and MOLT-4 cells. Similarly, the bromovinyl compounds did not affect the in vitro antitumor activities of arabinosylcytosine, 5-fluorouracil, and 5-fluoro-2'-deoxyuridine. The anti-varicellazoster virus activity of BV-araU was not influenced by azidothymidine, 2',3'-didehydro-2',3'-dideoxythymidine, or arabinosylcytosine, whereas relatively high concentrations of fluorinated antitumor agents enhanced the anti-varicella-zoster virus activity.

show abstract

“…In this study, we compared the antiviral activity of A-5021 with those of ACV and PCV against HSV-1, HSV-2, VZV, and HCMV by a plaque reduction assay with a selection of human cells, because antiviral activity is influenced by the cells used (5,13). The results show that whichever the cells used, A-5021 was the most potent of the three compounds against all wild-type herpesviruses tested (Table 1).…”

Section: Discussionmentioning

confidence: 99%

Antiherpesvirus Activities of (1′ S ,2′ R )-9-{[1′,2′-Bis(hydroxymethyl)cycloprop-1′-yl]methyl}guanine (A-5021) in Cell Culture

Ono

Ohmura

Suzuki

et al. 1998

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Antiherpetic activity of (1′S,2′R)-9-{[1′,2′-bis(hydroxymethyl)cycloprop-1′-yl]methyl}guanine (A-5021) was compared with those of acyclovir (ACV) and penciclovir (PCV) in cell cultures. In a plaque reduction assay using a selection of human cells, A-5021 showed the most potent activity in all cells. Against clinical isolates of herpes simplex virus type 1 (HSV-1,n = 5) and type 2 (HSV-2, n = 6), mean 50% inhibitory concentrations (IC50s) for A-5021 were 0.013 and 0.15 μg/ml, respectively, in MRC-5 cells. Corresponding IC50s for ACV were 0.22 and 0.30 μg/ml, and those for PCV were 0.84 and 1.5 μg/ml, respectively. Against clinical isolates of varicella-zoster virus (VZV, n = 5), mean IC50s for A-5021, ACV, and PCV were 0.77, 5.2, and 14 μg/ml, respectively, in human embryonic lung (HEL) cells. A-5021 showed considerably more prolonged antiviral activity than ACV when infected cells were treated for a short time. The selectivity index, the ratio of 50% cytotoxic concentration to IC50, of A-5021 was superior to those of ACV and PCV for HSV-1 and almost comparable for HSV-2 and VZV. In a growth inhibition assay of murine granulocyte-macrophage progenitor cells, A-5021 showed the least inhibitory effect of the three compounds. These results show that A-5021 is a potent and selective antiviral agent against HSV-1, HSV-2, and VZV.

show abstract

Different Antiviral Potencies of BV‐araU and Related Nucleoside Analogues against Herpes Simplex Virus Type 1 in Human Cell Lines and Vero Cells

Abstract: Antiviral potencies against herpes simplex virus type 1 (HSV-1) of 1-ƒÀ-

Cited by 15 publications

References 13 publications

Evaluation of Antiherpetic Compounds Using a Gastric Cancer Cell Line: Pronounced Activity of BVDU against Herpes Simplex Virus Replication

Evaluation of Antiherpetic Compounds Using a Gastric Cancer Cell Line: Pronounced Activity of BVDU against Herpes Simplex Virus Replication

In vitro drug combination of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil with anti-human immunodeficiency virus or anticancer nucleosides

Antiherpesvirus Activities of (1′ S ,2′ R )-9-{[1′,2′-Bis(hydroxymethyl)cycloprop-1′-yl]methyl}guanine (A-5021) in Cell Culture

Contact Info

Product

Resources

About